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Lauren Bolcar

Comment- Second Draft

PATENTING THE HUMAN BODY: MYRIAD, PROMETHEUS, AND THE FUTURE OF PATENTABLE
SUBJECT MATTER IN THE UNITED STATES

I.

INTRODUCTION

In 1990, the U.S. Human Genome Project officially began efforts to map the entire
human genome. 1 The international project lasted thirteen years and cost approximately $2.7
billion.2 In addition to gaining valuable insight about the human genetic code, researchers are
working to develop disease diagnostic tests and treatments using Deoxyribonucleic Acid (DNA)
analysis. 3 Diagnostic testing for genetic disorders has increased steadily over the past two
decades. 4 Over 350 biotechnology products are currently in clinical trials; many of these are
based on genetic research. 5 A 2005 study found that nearly 20% of human genes are explicitly
claimed in U.S. patents. 6 Many of these patents cover genes associated with numerous diseases,
such as Alzheimer's disease,7 cystic fibrosis, 8 Canavan disease,9 and asthma. 10
Researchers seek patents for gene sequences in order to provide incentives that are
critical to downstream investment, which will, in turn, lead to further discoveries on which

1

_

U.S. Dep't. ofEnergy Office of Sci., About the Human Genome Project, Genomics.engergy.gov.,
http://www.ornl.gov/sciltechresources/Human_Genome/projectJabout.shtml (last updated Sept. 19, 2011).
2
See Nat'l Human Genome Research Inst., Nat' I Institutes of Health, The Human Genome Project Completion:
Frequently Asked Questions, http://www.genome.gov/11006943 (last updated Oct. 30, 2010).
3
/d. ("Individualized analysis based on each person's genome will lead to a very powerful form of preventive
medicine.... Then, through our understanding at the molecular level of how things like diabetes or heart disease or
schizophrenia come about, we should see a whole new generation of interventions, many of which will be drugs that
are much more effective and precise than those available today.").
4
Gert Matthijs & Gert-Jan B. Van Ommen, Gene Patents: From Discovery to Invention. A Geneticist's View, in
GENE PATENTS AND COLLABORATIVE LICENSING MODELS: PATENT POOLS, CLEARINGHOUSES, OPEN SOURCE
MODELS AND LIABILITY REGil\IIES 311, 316 (Geertrui Van Overwalle ed., Cambridge University Press 2009).
5 Jd
6
Gloria Bevan & Kyle Jensen, Intellectual Property Landscape of the Human Genome, 310 SCI., 239-40,239
(2005).
7
Ronald Kotulak, Taking License With Your Genes: Biotech Firms Say They Need More Protection, CHI. TRIB.,
Sept. 12, 1999, http://articles.chicagotribune.com/1999-09-12/news/9909120225_1_gene-patents-patent-officemolecular-pathology-laboratory.
8
Id
9
Arthur Allen, Who Owns My Disease?, 26 MOTHER JONES 52-59 (2001).
1
--~-------- ~ U.S._Patent No_,_6,_Q37,14_9 ([Iled_Mar.J4, 2000), _ -~---- __ _
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genetic tests are based. 11 In the pharmaceutical and diagnostic healthcare industry, patent
protection is viewed as crucial in aiding the recouping of substantial costs associated with the
discovery and development of new therapies. 12 Patent-holders claim that without patent
protection, there would be little motivation to make the discoveries in the first place, or to
publish them. 13 The corporation Myriad Genetics has argued that if gene patents are no longer
allowed, future developments in genetic diagnostic testing and therapies will slow or cease, or
will not be disclosed in order to maintain trade-secret protection. 14
There is a great deal of controversy surrounding gene patents. 15 Famous author Michael
Crichton expressed the fears of many researchers, doctors, and patients when he wrote the
following in a New York Times opinion editorial: "[y]ou, or someone you love, may die because
of a gene patent that shouid never have been granted in the first piace. Sound far-fetched?
Unfortunately, it's only too real." 16 A 2005 survey of laboratory directors in the United States
sought to quantify the impact of gene patents on the ability of doctors to perform research and
provide clinical genetic testing services. 17 The study found that 53% of respondents decided not
to develop or perform a test or service for clinical or research purposes because of a patent, 18 and

11
Beyan & Jensen, supra note 6; Mildred K. Cho et al., Effects ofPatents and Licenses on the Provision of Clinical
Genetic Testing Services, 5 J. MOLECULAR DIAGNOSTICS 3,4 (2003),
http://www .ncbi.nlm.nih.gov/pmc/articles/PMC 19073 68/pdf/0 108.pdf.
12
Cho, supra note 11 at 3
this industry particularly, patents are seen as necessary to enhance an inventor's
ability to recoup the substantial investments of many ears and hundreds of millions of dollars necessary to bring a
new drug or device to market."); Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 702
F.Supp.2d 181,210-11 (S.D.N.Y. 2010).
13
Kotula.~ 7 supra note 7.
14
Brief for Appellant at 4 Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329, 1350
(Fed. Cir. 2011) (No. 2010-1406).
15
Jordan Paradise, European Opposition to Exclusive Control over Predictive Breast Cancer Testing and the
Inherent Implications for U.S. Patent Law and Public Policy: A Case Study ofthe Myriad Genetics' BRCA Patent
Controversy, 59 FOOD & DRUG L.J. 133, 133 (2004).
16
Michael Crichton, Patenting Life, N.Y. TIMES, Feb. 13,2007, http://www.nytimes.com/2007/02/13/opinion/
13 crichton.html.
17
Cho, supra note 11, at 3.
18
Jd at 5.

ein
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67% reported a decreased ability to conduct research. 19 The American Society of Human
Genetics found similar results in a separate survey, where 46% of respondents felt that patents
had limited or delayed their research.

20

Along with gene patents, diagnostic method patents have been the source of recent
controversy. 21 Since 2006 three cases involving diagnostic method patents have reached the
Supreme Court of the United States22 with the potential for another case in the near future. 23
These cases are similar in that the diagnostic method patent in question involves a transformative
or quantitative element originating within the human body: amino acid levels in a patient's
blood,24 drug metabolite concentrations,25 patent immunization on a determined schedule,26 or
cancer cell growth rates in the presence of potential therapeutics. 27
This Comment will discuss the judicial precedent surrounding diagnostic method claims
utilizing scientific breakthroughs in genetic research, with an emphasis on the recent and
publicized Association for Molecular Pathology v. US. Patent and Trademark Office
("Myriad'').Z 8 It will argue that under current patent law, Myriad was correctly decided, yet due
to critical public policy concerns, the time may have arrived for a reinterpretation of what is
considered patent-eligible subject matter. Part II is a brief overview what is considered

19

Jd. at 7.
Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F.Supp.2d 181,208 (S.D.N.Y. 2010).
21
Asher Hodes, Note, Diagnosing Patentable Subject Matter, 26 BERKELEY TECH. L.J. 225, 230.
22
Lab. Corp. of America Holdings v. Metabolite Laboratories, Inc., 548 U.S. 124, 125 (2006) (dismissing writ of
certiorari as improvidently granted); Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 581 F.3d 1336
(Fed. Cir. 2009), vacated, 130 S.Ct. 3543 (2010), rev'd, 628 F.3d 1347 (Fed. Cir. 2010), cert. granted, 131 S.Ct.
3027 (U.S. Jun 20, 2011) (No. 10-1150); Classen Immunotherapies, Inc. v. Biogen IDEC, 130 S.Ct. 3541 (2010)
(vacating judgment and remanding for further consideration in light of Bilski v. Kappos, 130 S.Ct. 3218 (2010)),
affdin part, rev'din part, vacated in part, 659 F .3d 1057 (Fed. Cir. 2011 ).
23
Hodes, supra note 21 at 225; Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329
(Fed. Cir. 2011),petitionfor cert.filed.
24
Metabolite Laboratories, Inc., 548 U.S. 125 (2006).
25
Prometheus, 581 F.3d at 1347.
26
Classen Immunotherapies, Inc. v. Biogen IDEC, 659 F.3d 1057 (Fed. Cir. 2011).
27
Ass'n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011).
28ld
20
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patentable under U.S. patent law. Parts III and IV discuss the patentability of DNA and method
claims, respectively. Part Vis dedicated to a study of the Myriad case, which represents the
intersection of diagnostic method patents and gene patenting. Part VI analyzes the impact of the

Myriad decision and the future of diagnostic method patenting.
II. UNITED STATES PATENT LAW-PATENT ELIGIBLE Sl.JBJECT MATTER

A United States patent confers upon the patentee an exclusive right to the patented
invention for twenty years after the date the patent application was filed with the United States
Patent and Trademark Office (USPT0)?9 In exchange for this right to exclude, the inventor
must publicly disclose the invention through the specification. 30 In order to be patent eligible,
the invention must meet several statutory requirements: it must concern patent-eligible subject
matter,31 it must be novel,32 and it must be non-obvious?3
Patent-eligible subject matter is defined by Section 101 of the Patent Act of 1952 as: "any
new and useful process, machine, manufacture, or composition of matter, or any new and useful
improvement thereof.... " 34 Under Section lOO(b) of the Patent Act, "[t]he term 'process'

35 U.S.C. §154(a)(2) (2011). The patent grants the patent holder ~'the right to exclude others from making, using,
offering for sale, or selling the invention throughout the United States or importing the invention into the United
States, a.11d, !fthe fu.yention is a process, of the right to exclude other-:; from using) offering for sale or selling
throughout the United States, or importing into the United States, products made by that process...." 35 U.S.C. §
154 (a)(l) (2011).
30
35 U.S.C § 112 (2011). "The specification shall contain a written description of the invention, and of the manner
and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the
art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the
best mode contemplated by the inventor of carrying out his invention. The specification shall conclude with one or
more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his
invention." The first and second paragraphs of §112 (aoove) provide the distinct disclosure requirements for patent
protection. This written information is collectively known as the patent specification. Accord F. SCOTTKEFF ET
AL., PRINCIPLES OF PATENT LAW: CASES AND MATERIALS 154-55 (Robert C. Clark et al. eds., 5th ed. 2011).
31
35 u.s.c. § 101 (2011).
32
35 u.s.c. § 102 (2011).
33
35 U.S.C. § 103(a) (2011). "A patent may not be obtained though the invention is not identically disclosed or
described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented
and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was
made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be
negatived by the manner in which the invention was made."
34
35 U.S.C. § 101 (2011).

29
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means process, art or method, and includes a new use of a known process, machine,
manufacture, composition of matter, or materia1."

35

The Supreme Court has interpreted the

definition of patent-eligible subject matter as describing "four independent categories of
inventions or discoveries that are eligible for protection: processes, machines, manufactures, and
compositions ofmatter."36 The Court has also recognized that Congress intended that the scope
of patentable subject matter should be given a broad interpretation.37 Indeed, one may describe
patent-eligible subject matter as "includ[ing] anything under the sun that is made by man."38
There are limitations, however, to what may be considered patent-eligible subject matter.
Supreme Court precedent "provides three specific exceptions to § 101 's broad patent-eligibility
principles: 'laws of nature, physical phenomena, and abstract ideas. "'39 As the number of
patents covering pioneering technologies increases, the courts have struggled to develop a clear
framework for determining patent eligibility under § 101, especially when the claimed invention
does not produce tangible results, or when public policy concerns call for limiting patentability.40
III.

PATENTABILITY OF DNA

The 1980 Supreme Court case Diamond v. Chakrabarty41 held that a live, man-made
microorganism was patentable under§ 101 as a "manufacture" or "composition ofmatter.',42
This proved to be a seminal decision on patentable subject matter, as thousands of patents
relating to genes and genetic material have been awarded since this case was decided. 43 In 1983,

35

35 U.S.C. § IOO(b) (2011).
Bilski v. Kappos, 130 S. Ct. 3218,3225 (2010).
37
Diamond v. Chakrabarty, 447 U.S. 303, 308 (1980) ("In choosing such expansive terms ... modified by the
comprehensive 'any,' Congress plainly contemplated that the patent laws would be given wide scope.").
38
ld at 309 (quoting the language of the Congressional Committee Reports accompanying the 1952 Patent Act).
39
Bilski, 130 S. Ct. at 3225 (quoting Chakrabarty, 447 U.S. at 309).
40
Stephen W. Chen, et al., Patent Protection in Medicine and Biotechnology: An Overview, 4 J. HEALTH & LIFE SCI.
L. 106, 132 (2011).
41
447 u.s. 303 (1980).
42
Chakrabarty, 447 U.S. at 303.
43
Jordan Paradise, European Opposition to F.xclusive f:nntrnl over Predictive Breast Cancer Testing and the
36
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the USPTO expanded the scope of patent protection available for genetic material by issuing the
first patents relating to "isolated DNA."44 In 1991, the CAFC held that claims for a "purified
and isolated DNA sequence" were valid and enforceable. 45 The USPTO has adopted this policy
regarding the patentability of isolated and purified DNA, acknowledging it as patent eligible
because "(1) an excised gene ... does not occur i11 that isolated form in nature, or (2) ... their
purified state is different from the naturally occurring compound."46
The Supreme Court has not yet defmitively ruled on the patentability of DNA.47 The
closest the Court has come to addressing this issue was in Laboratory Corp ofAmerica Holdings
v. Metabolite Laboratories, Inc. ("LabCorp"). 48 Metabolite Laboratories was the licensee of a
patent that claimed methods for detecting vitamin Band folic acid deficiencies in patients.49
Metabolite sued LabCorp for patent infringement when LabCorp began using a similar test
developed by another company and discontinued royalty payments to Metabolite. 5° Specifically,
the disputed claim was for a method of "detecting vitamin B deficiencies by measuring amino
acid levels in a patient's blood and then correlating those amino acid levels with vitamin B
levels."51 LabCorp argued that this claim (claim 13 of Metabolite's patent) was invalid for a
variety of reasons, 52 but did not raise the issue of invalidity under § 101 until their appeal to the

Inherent Implications for US. Patent Law and Public Policy: A Case Study ofthe Myriad Genetics' BRCA Patent
Controversy. 59 FOOD & DRUG L.J. 133, 133 (2004) ("Between 1980 and 2001, the U.S. Patent and Trademark
Office (USPTO) awarded over 8,000 patents on genes and genetic material, including at least 1,500 claiming
sequences of human genetic material.").
44
See U.S. Patent No. 4,680,264 claim 27 (filed July 1, 1983) (claiming a recombinant vector rather than genomic
DNA).
45
Amgen Inc. v. Chugai Pharm. Co., 927 F.2d 1200, 1219 (Fed. Cir. 1991).
46
USPTO Examination Guidelines http://www. uspto.gov/web/o:ffices/com/sollnotices/utilexmguide.pdf (200 1).
47
Petition for Writ of Certiorari, Ass'nfor Molecular Pathology, 16 (2011).
48
Lab. Corp. of America Holdings v. Metabolite Laboratories, Inc., 548 U.S. 124, 125 (2006) (Breyer, JJ.,
dissenting).
49
Metabolite Laboratories, Inc. v. Lab. Corp. of America Holdings, 370 F.3d 1354, 1358-59 (Fed. Cir. 2004).
50
Metabolite Laboratories, Inc., 370 F.3d at 1359.
51
Hodes, supra note 21 at 230; accord U.S. Patent No. 4,940,658 (filed Nov. 20, 1986).
52
Metabolite Laboratories, Inc., 370 F.3d at 1365 ("LabCorp argues that claim 13 is invalid on grounds of
indefmiteness, lack of written description and enablement, anticipation, an~ obviousness.").
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Supreme Court. 53 The Supreme Court initially granted certiorari, yet later dismissed it as
improvidently granted, 54 perhaps because the lower courts had not yet had an opportunity to rule
55

on that issue. Consequently, the CAFC holding that the disputed claim is valid and that
LabCorp infringed the claim56 is still valid.
IV. PATENTABILITY OF METHOD CLAIMS

The Supreme Court has held that a valid process claim cannot claim "laws of nature,
natural phenomena, [or] abstract ideas."57 For example, an abstract mathematical formula
cannot be patented. 58 The Court implemented these restrictions in order to discourage patentees
from attempting to claim abstract subject matter by limiting the formula to a specific
technology. 59 These restrictions exist in order to prevent preemption, wherein a patent bars all
application of a fundamental principle. 60
A. The Development and Application ofthe Machine-or-Transformation Test
In Gottschalk v. Benson61 the Court recognized that the "[t]ransformation and reduction

of an article 'to a different thing' is the clue to the patentability of a process claim that does not
include particular machines."62 The Court of Appeals for the Federal Circuit (''CAFC") later

53

Brief for the United States as Amicus Curiae at 15-19, Lab. Corp. of America Holdings v. Metabolite
Laboratories, Inc., 548 U.S. 124 (2006) (No. 04-607), 2005 WL 3533248; see also Metabolite Laboratories, Inc.,
548 U.S. at 132 (''Question Three of the petition asks ' [w ]hether a method patent ... directing a party simply to
correlat[e] test results can validly claim a monopoly over a basic scientific relationship ... such that any doctor
necessarily infringes the patent merely by thinking about the relationship after looking at a test result.") (citation
omitted).
54
Metabolite Laboratories, Inc., 548 U.S. at 125-26.
55
Metabolite Laboratories, Inc., 370 F.3d at 1368.
56
Id at 1365.
57
Diamond v. Diehr, 450 U.S. 175, 185 (1981).
58
Gottschalk v. Benson, 409 U.S. 63,71 (1972).
59
Diehr, 450 U.S. at 192-93 ("We view respondents' claims as nothing more than a process for molding rubber
products and not as an attempt to patent a mathematical formula .... A mathematical formula as such is not
accorded the protection of our patent laws ... and this principle cannot be circumvented by attempting to limit the
use of the formula to a particular technological environment." (citations omitted)).
60
Tiana Leia Russell, Unlocking the Genome: The Legal Case Against Genetic Diagnostic Patents, 16 MARQ.
lNTELL. PROP. L. REV. 81, 91 (2012).
61
409 U.S. 63 (1972).
62
Rensnn, 409 l J.S. at 70.
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cited this standard as "a definitive test" for determining patent eligibility of a process claim in In

re Bilski. 63 The Supreme Court held that the mathematical algorithm was not a "process" but an
abstract idea and therefore unpatentable. 64 The Court explained that to hold otherwise "would
wholly pre-empt the mathematical formula and in practical effect would be a patent on the
algorithtn itself."65

In Parker v. Flook,

66

the Court established "that limiting an abstract idea to one field of

use or adding token postsolution components did not make the concept patentable." 67 However,
the Court explained in Diamond v. Diehr that claims containing mathematical formulas which
are tied to a valid application of a natural phenomenon or abstract idea may be patentable as a
whole. 68 Under Diehr, when a claim contains a fundamental principle (such as a mathematical
tbrmula, natural phenomenon, or scientific principle),

~~an

inquiry must be made into whether the

claim is seeking patent protection for u~at formula i11 the abstract." 69 In other words, although
the entire claim must be considered when determining patentability, "the inventive concept
cannot derive solely from the fundamental principle."70

In Bilski v. Kappos

71

the CAFC drew on Supreme Court case law to articulate a two-

prong "definitive test" for determining process patent eligibility. The court determined that "[a]

63

In re Bilslti, 545 F.3d 943 (Fed. Cir. 2008) ("The Supreme Court, however, has enunciated a definitive test to
determine whether a process claim is tailored narrowly enough to encompass only a particular application of a
fundamental principle rather than to pre-empt the principle itself. A claimed process is surely patent-eligible under §
101 if: (1) it is tied to a particular machine or apparatus, or (2) it transforms a particular article into a different state
or thing.").
64
Benson, 409 U .S.at 71.
65
!d. at 72.
66
437 u.s. 584 (1978).
67
Bilski, 130 S. Ct. at 3231.
68
Diehr, 450 U.S. at 192 ("[W]hen a claim containing a mathematical formula implements or applies that formula in
a structure or process which, when considered as a whole, is performing a function which the patent laws were
designed to protect (e. g., transforming or reducing an article to a different state or thing), then the claim satisfies the
requirements of§ 101.").
69
Id 450 U.S. at 191.
70
Russell, supra note 60 at 81.
71
130 S. Ct. 3218 (2010).
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claimed process is surely patent-eligible under§ 101 if: (1) it is tied to a particular machine or
apparatus, or (2) it transforms a particular article into a different state or thing."72 A patentee
need only show the process claim satisfies one of the two prongs to patent-eligible.

73

Following

the analysis of Benson, Flook, and Diehr, the CAFC explained that "the use of a specific
machine or transformation of an article must impose meaningful limits on the claim's scope to
impart patent-eligibility," and "the involvement of the machine or transformation in the claimed
process must not merely be insignificant extra-solution activity."74 Essentially, the purpose of
the claimed process must be the transformation of the article. 75
The claimed invention at issue in Bilski v. Kappos involved a method of protecting
buyers and sellers of commodities in the energy market against the risk of price changes. 76 The
CAFC framed the issue as determining what "process" means as defined in § 101, and how to
establish whether a particular claim is a "new and useful process."77 The CAFC concluded that
the "machine-or-transformation test" was "the sole test for governing § 101 analyses"78 and thus
was the "test for determining patent eligibility of a process under § 101. " 79 Applying the
machine-or-transformation test, the CAFC held the application at issue was not patentable as it
satisfied neither the machine 80 nor transformation81 prong of the test.
The Supreme Court granted certiorari to clarify the proper use of the machine-ortransformation test. According to the Court, the CAFC "incorrectly concluded that this Court
72

In re Bilski, 545 F.3d 943, 953 (Fed. Cir. 2008).
Id at 961.
74
Id at 961-62 (citations omitted).
75
Id at 962.
76
Bilski, 130 S. Ct. at 3223 .
7
.7 In re Bilski, 545 F.3d 943, 951 (Fed. Cir. 2008).
78
ld. at 955.
79
I d. at 956.
80
Id at 962 e'As to machine implementation, Applicants themselves admit that the language of claim 1 does not
limit any process step to any specific machine or apparatus.").
81
I d. at 963 ("We hold that the Applicants' process as claimed does not transfonn any article to a different state or
thing.").
73
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has endorsed the machine-or-transformation test as the exclusive test." 82 Rather, the Court
categorized the test as "a useful and important clue, an investigative tool, for determining
whether some claimed inventions are processes under§ 101."83 The Court explained that while
the machine-or-transformation test may work well for determining patentability of physical or
ta11gible inventions, it ¥/ould "create u..11certainty" as to the patentability of more complex subject

matter. 84 The Court warned that too narrow a test might render newer and more nuanced
technologies unpatentable. 85 Interestingly, the CAFC recognized such an issue in its own
analysis of the Bilski case, and predicted the Supreme Court expanding the patentability test in
the future. 86 The Court ultimately affirmed the decision of the CAFC, holding the claims
unpatentable as abstract ideas, yet the Court did so by confining its analysis to the principles
established in Benson, Flook, and Diehr. 81 Under these cases, to detennine if a patent is
preemptive, ''the key consideration is whether the patent threatens to (a) v1holly preempt the

fundamental principle or (b) be the only practical and useful application of the principle."88
B. Patentability ofDiagnostic Method Claims

82

Bilski, 130 S. Ct. at 3226 (201 0).
Id at 3227.
84
Jd ("[T]he machine-or-transformation test would create uncertainty as to the patentability of software, advanced
diagnostic medicine techniques, and inventions based on linear programming, data compression, and the
manipulation of digital signals.").
85
Jd ("In the course of applying the machine-or-transformation test to emerging technologies, courts may pose
questions of such intricacy and refinement that they risk obscuring the larger object of securing patents for valuable
inventions without transgressing the public domain.").
86
In re Bilski, 545 F.3d at 956 ("[W]e agree that future developments in technology and the sciences may present
difficult challenges to the machine-or-transformation test, just as the widespread use of computers and the advent of
the Internet has begun to challenge it in the past decade. Thus, we recognize that the Supreme Court may ultimately
decide to alter or perhaps even set aside this test to accommodate emerging technologies. And we certainly do not
rule out the possibility that this court may in the future refme or augment the test or how it is applied. At present,
however, and certainly for the present case, we see no need for such a departure and reaffirm that the machine-ortransformation test, properly applied, is the governing test for determining patent eligibility of a process under §
10 1.").
87
Bilski, 130 S. Ct. at 3229-30 ("Rather than adopting categorical rules that might have wide-ranging and
unforeseen impacts, the Court resolves this case narrowly on the basis of this Court's decisions in Benson, Flook,
and Diehr, which show that petitioner's claims are not patentable processes because they are attempts to patent
abstract ideas.").
88
Russell, supra note 60 at 81.
83
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There are three types of process patents typically related to the medical field: (1) medical
procedures that do not require the use of any patented medical products, (2) methods for using a
patented drug or device, and (3) techniques for isolating chemical compounds or building
devices. 89 In 2009, the CAFC upheld the validity of two method patents owned by Prometheus
Laboratories, Inc. (Prometheus). 90 The patents claim methods for optimizing the proper dosage
of thiopurine drugs, which are used to treat both gastrointestinal and non-gastrointestinal
autoimmune diseases. 91 The Prometheus patents involve a process for the measurement of two
metabolites in order to "optimize therapeutic efficacy while minimizing toxic side effects."92
The patents contain two separate steps: "administering" a drug ... to a patient, and
"determining" the levels of drug metabolites ... in the patient. 93 The measured metabolite levels
are then compared to a range of metabolite concentration contained in the claims, '"wherein' the
measured metabolite levels 'indicate a need' to increase or decrease the level of drug to be
administered so as to minimize toxicity and maximize efficacy of the treatment."94
Prometheus marketed a test that used the technology described in the patents. 95 In 2004
Mayo Collaborative Services and Mayo Clinic Rochester (Mayo) announced it would be selling

89

Margaret Kubick, Note, An Uncertain Future: The Impact ofMedical Process and Diagnostic Method Patents on
Healthcare in the United States, 9 Nw. J. TECH. & lNTELL. PROP. 280, 14, (2010).
90
Prometheus Laboratories, Inc. v. Mayo Collaborative Services, 581 F.3d 1336 (Fed. Cir. 2009).
91
Prometheus, 581 F.3d at 1339; U.S. Patent No. 6,355,623 (filed Apr. 8, 1999) (describing a ~'[m]ethod of treating
IBD/Crobn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent
dosage"); U.S. Patent No. 6,680,302 (filed Dec. 27, 2001) (describing "[m]ethods of optimizing drug therapeutic
efficacy for treatment of immune-mediated gastrointestinal disorders").
92
Prometheus, 581 F.3d at 1339.
93
94

Jd

Jd (quoting language from the patents at issue. Claim 1 ofU.S. Patent No. 6,355,623 is representative of the
claims asserted by Prometheus: "A method of optimizing therapeutic efficacy for treatment of an immune-medicated
gastrointestinal disorder, comprising: (a) administering a drug providing 6-thioguanine to a subject having said
immune-medicated gastrointestinal disorder; and (b) determining the level of 6-thioguanine in said subject having
said immune-medicated gastrointestinal disorder, wherein the level of 6-thioguanine less than about 230 pmol per
8
8x 10 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject
and wherein the level of 6-thioguanine greater than about 400 pmol per Sx 108 red blood cells indicates a need to
decrease the amount of said drug subsequently administered to said subject.")
95
ld at 1340.
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its own test, which measured the same metabolites as the Prometheus test, but used different
metabolite levels to determine toxicity.96 Prometheus sued Mayo for patent in:fringement. 97 The
District Court for the Southern District of California granted Mayo's motion for summary
judgment of invalidity under§ 101, finding that "the 'administering' and 'determining' steps are
merely necessary data-gathering steps for any use of the correlations and that as constructed5 the
fmal step ... is only a mental step."98
On appeal the CAFC began its analysis by reviewing the machine-or-transformation test
for process patent eligibility under § 101 it had recently utilized in the Bilski decision. 99 It held
that the method of treatment claims were patentable subject matter as it satisfied the
transformation prong of the test. 100 The court reasoned that the transfonnative step in the process
was when the body metabolized the administered drug. 101 The fact that t1i.e change of the
administered drug into Lherapeutic metabolites relied on natural process was not dispositive, for
"quite literally every transformation of physical matter can be described as occurring according
to natural processes and naturallaw." 102 The CAFC likewise found the determining steps
transformative, as the levels of metabolite could not be ascertained without some form of
manipulation or modification of the bodily sample to determine the concentration of the
metabolites therein. 103 The court then concluded that the "administering" and "determining"
steps were essential to the claimed process, and therefore were not merely data-gathering or

Jd
Jd
98
Prometheus, 581 F.3d at 1341 (internal quotations omitted).
99
ld. at 1342-43.
100
/d. at 1344.
101
Jd at 1346 ("The drugs do not pass through the body untouched without affecting it. In fact, the transformation
that occurs, viz., the effect on the body after metabolizing the artificially administered drugs, is the entire purpose of
administering the drugs: the drugs are administered to provide 6-TG, which is thought to be the drugs' active
metabolite in the treatment of the disease, to a subject.").
102 Jd.
103
Prometheus, 581 F.3d at 1347.
96
97
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"insignificant extra-solution activity." 104 The CAFC agreed with the district court that the
"wherein" clauses of the claims were mental steps, but this did not render the entire process
unpatentable. 105 The CAFC emphasized that the entire claimed process must be viewed as a
whole. 106 Finally, the CAFC disagreed with the fmding of the district court that the claims
wholly preemptive of the correlations between metabolite levels and toxicity or efficacy. 107 The
CAFC returned to the machine-or-transformation test, 108 and determined that "[t]he inventive
nature of the claimed methods stems not from preemption of all use of these natural processes,
but from the application of a natural phenomenon in a series of transformative steps comprising
particular methods oftreatment." 109
Following the CAFC ruling the Supreme Court granted certiorari, vacated the judgment
in light of its Bilski decision, and remanded the case back down to the CAFC for further
consideration. 110 On remand the CAFC requested briefs from both parties addressing the effect
of the Bilski decision the case at bar. 111
The second Prometheus opinion follows a similar line of reasoning to the frrst opinion,
despite the additional guidance from the Bilski decision. The CAFC recognized that in light of
Bilksi, the issue of patent eligibility turned on whether the Prometheus claims were drawn to a

natural phenomenon, which would result in complete preemption if patented, or "whether the
claims were drawn only to a particular application of that phenomenon, as in Diehr. " 112
According to the CAFC, the Bilski decision did not impose a "wholly different analysis or a
104
105
106
107
108

ld at 1348.
Jd ('~A subsequent mental step does not, but itself, negate the transformative nature of prior steps.").
Jd at 1349.
Jd.

Prometheus. 581 F.3d at 1349("[B]ecause the claims meet the machine-or-transformation test, they do not
preempt a fundamental principle.").
109 ld.
110
Prometheus, 130 S. Ct. 3543 (2010).
111
Prometheus, F.3d at 1353.
112
Id at 1354.
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different result on remand." 113 The Bilski decision served only to correct the CAFC's original
presumption that the machine-or-transformation test was the exclusive test for process
patentability. 114 As a result, the CAFC once again held the diagnostic claims as patentable under
§ 101, using much ofthe same analysis as in the original opinion. 115

The Supreme Cou.rt again gr8.nted certiorari Ln June 2011, u 6 which seemingly indicates
the CAFC misinterpreted the lesson of Bilski. On remand, Mayo argued that the Bilski decision
"reaffirmed that preemption is the controlling standard for§ 101" under Supreme Court
precedent, and ~'made clear that while a machine-or-transformation test may inform the analysis,
the test is not outcome determinative." 117 Mayo maintains that Prometheus's claims are invalid
as preempting all practical use of a natural phenomenon, and that the claims satisfy the machine-

or-transfonuation test "is merely insigHifica.t"lt post-solution activity." 118
V. MYRIAD: iNTERSECTION OF DIAGNOSTIC METHOD PATENTS AND GENETIC TESTING
The Myriad case is especially compelling because it is an amalgamation of diagnostic
method and gene patents. Myriad Genetics held seven U.S. patents regarding two isolated
human genes (BRCA1 and BRCA2), mutations of which were associated with a predisposition to
breast and ovarian cancers. 119 The Myriad patents originated with an international research
initiative focused on breast cancer research. Several European and American research
laboratories founded the Breast Cancer Linkage Consortium (Consortium) in 1989 to promote
the open exchange of data and ideas with the expressed goal of discovering the genetic basis of

113

Jd at 1355.
ld
115
ld ("Thus, the Court did not disavow the machine-or-transformation test. And, as applied to the present claims,
the 'useful and important clue, an investigative tool,' leads to a clear and compelling conclusion, viz., that the
present claims pass muster under § I 0 I. They do not encompass laws of nature or preempt natural correlations.").
116
Prometheus, 131 S. Ct. 3027.
117
Prometheus, 628 F.3d at I354.
ns Id
119
Ass'nfor Molecular Pathology, 653 F.3d at 1334.
114
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breast cancer.

120

In 1990 a team from the Consortium localized the BRCA1 gene. 121 A year later another
member of the Consortium, Mark Skolnick from the University of Utah, founded Myriad
Genetics in order to capitalize on the research once the complete gene was sequenced.
successfully cloned and sequenced the BRACI gene in 1994.

123

122

Myriad

In the United Kingdom in 1994,

the Institute of Cancer Research localized the BRAC2 gene. 124 It was further characterized by
Myriad.125
Beginning in 1995, Myriad sought U.S. patent protection for the isolated BRCA1/2 genes
as well as methods of diagnostic testing for the genetic mutations contained therein. 126 The
European Patent Office (EPO) granted Myriad and co-inventors several patents based on these
genes. 127 The method claims patented by Myriad have been divided into two categories: method
for "comparing" and "analyzing" DNA sequences, 128 and method for screening potential cancer
therapeutics through changes in cell growth rates. 129 The second type of claim is found in patent
5,747,282 (the '282 patent) and is directed to "a method for identifying potential cancer
therapeutics by utilizing cells into which an altered BRCA1 gene known to cause cancer has

120

Paradise, supra note 15 at 143.
Matthijs & Van Ommen, supra note 4 at 319; Paradise, supra note 81, at 143.
122
Matthijs & Van Ommen, supra note 4 at 320.
123 ld.
124 ld.
125 ld.
126
U.S. Patent No. 5,747, 282 (filed June 7, 1995) (claimmg ''[a]n isolated DNA codmg for a BRCA 1 polypeptide.
. . ." and "a method for screenmg potential cancer therapeutics" usmg "an BRCA 1 gene ....");U.S. Patent No.
5,837,492 (filed Apr. 29, 1996) (claimffig "[a]n isolated DNA molecule codmg for a BRCA2 polypeptide....");
U.S. Patent No. 5,693,473 (filed June 7, 1995) (claiming "[a]n isolated DNA comprising an altered BRCAl DNA ...
."); U.S. Patent No. 5,709,999 (filed June 7, 1995) ( claimffig "[a] method for detecting a germlffie alteration in a
BRCA1 gene ....''); U.S. Patent No. 5,710,001 (filed June 7, 1995) (claiming "[a] method for screening a tumor
sample from a human subject for a somatic alteration in a BRCA1 gene in said tumor....");U.S. Patent No.
5,753,441 (filed Jan. 5, 1996) (claiming "[a] method for screening germlffie of a human subject for an alteration of a
BRCAI gene ...."); U.S. Patent No. 6,033,857 (filed Mar. 20, 1998) (claiming "A method for identi:fymg a mutant
BRCA2 nucleotide sequence in a suspected mutant BRCA2 allele....").
127
Matthijs & Van Ommen, supra note 4 at 320.
128
Ass'nfor Molecular Pathology, 653 F.3d at 1355.
129
ld at 1357.
121
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been inserted." 130 The growth rates of the artificial cancer cells are compared to determine the
efficacy of a potential cancer therapeutic. 131
In 2009 the ACLU brought suit against Myriad Genetics on behalf of several medical
organizations, researchers, genetic counselors, and patients to challenge the patentability of
fifteen composition and method claims in U.S. patents relating to human genetics. i3l The ACLU
charged that the Myriad patent claims were invalid as covering "products of nature, laws of
nature and/or natural phenomena, and abstract ideas or basic human knowledge or thought."

133

The Southern District ofNew York held that the patents claiming at isolated DNA
sequences, as well as the patents claiming comparisons of DNA sequences, were unpatentable
under § 101. 134 On appeal, the CAFC majority reversed the district court's holding that isolated
Dl"~A is unpatentable w1der § 101. 135 However, each member of the tt.uee-panel judge Wiote a

separate opinion on this issue. 136 While a great deal of the attention surrounding this case has
been focused on the claims regarding the patentability of DNA, 137 due to the recent controversy
generated by such patents, the CAFC's conclusions regarding the patentability of Myriad's

130

Id at 1337; See also U.S. Patent No. 5,747, 282 (filed June 7, 1995) (claiming specifically ''A method for
screening potential cancer therapeutics which comprises: growing a transformed eukaryotic host cell containing an
altered BRCA1 gene causing cancer in the presence of a compound suspected ofbeing a cancer therapeutic, growing
said transformed eukaryotic host cell in the absence of said compound, determining the rate of growth of said host
cell in the presence of said compound and the rate of growth of said host cell in the absence of said compound and
comparing the growth rate of said host cells, wherein a slower rate of growth of said host cell in the presence of said
compound is indicative of a cancer therapeutic.").
131
Ass 'n for Molecular Pathology, 702 F .Supp.2d at 237.
132
Ass'nfor Molecular Pathology, 653 F.3d at 1333-34; Joshua D. Sarnoff, Patent Eligible Medical and
Biotechnology Inventions after Bilski, Prometheus, and Myriad, 19 TEX. INT'LPROP. L.J. 393,408 (2011).
133
Ass'nfor Molecular Pathology, 702 F.Supp.2d at 184.
134
Id. at 185.
135
Ass'nfor Molecular Pathology, 653 F.3 at 1350.
136
See generally id at 1350 (concluding that claims relating to isolated DNA are patent~eligible subject matter under
§ 101, regardless of limitation to eDNA or not); id. at 1361 (Moore, J., concurring-in-part) (emphasizing certain
chemical considerations of particular importance); id at 1373 (Bryson, J., concurring-in-part and dissenting-in-part)
(fmding isolated DNA claims not directed to patentable subject matter).
137
E.g., Gene Quinn, As Predicted, Federal Circuit Rule Isolated DNA Patentable, IPWatchdog (July 29,2011,2:12
PM), http://ipwatchdog.com/20 11/07/29/federal-circuit-rules-isolated-dna-patentable/id= 18487/; Federal Circuit:
Isolated Human DNA Molecules are Patentable, Patently-0 (July 29, 2011, 12:32 PM),

http://www.patentlyo.com/patent/20 11/07/federal-circuit-isolated-human-dna-molecules-are-patentable.html.
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diagnostic method claims deserve attention as well.

138

The CAFC affirmed the district court's ruling that the "comparing" and ''analyzing"
claims were unpatentable under § 101.

139

The CAFC found that the claims were drawn to ''the

abstract mental process of comparing two nucleotide sequences" and declined to extend
Myriad's claims to include the extraction and sequencing steps of DNA preparation prior to
analysis. 140 The CAFC distinguished its earlier Prometheus decision, which held that the claims
at issue contained transformative steps as written, and the "determining" step of the claims "was
both transformative and central to the purpose of the claims." 141 In contrast, the CAFC found the
Myriad claims did not include a determinative, gene sequencing step. 142 The comparison
between gene sequences could be accomplished by inspection alone. 143
However, the CAFC disagreed with the district court regarding the patentability of the
second type of method claim at issue (the '282 patent). Again the CAFC referenced its
Prometheus decision when analyzing the Myriad claim. 144 The court found that the claim
included the transformative steps of: "(1) 'growing' host cells transformed with an altered
BRCAl gene in the presence or absence of a potential cancer therapeutic, (2) 'determining' the
growth rate of the host cell with or without the potential therapeutic, and (3) 'comparing' the
growth rate of the host cells." 145 These steps were found to be "central to the purpose of the

138

Hodes, supra note 21 at 230.
ld. at 1357.
140
I d. (''The claims do not specify any action prior to the step of 'comparing' or 'analyzing' two sequences; the
claims recite just the one step of 'comparing' or 'analyzing.' Moreover, those terms' plain meaning does not
include Myriad's proposed sample-processing steps; neither comparing nor analyzing means or implies 'extracting'
or 'sequencing' DNA or otherwise 'processing' a human sample.").
139

141Jd.
142

Ass'nfor Molecular Pathology, 653 F.3d at 1357.
ld.
144 ld.
145 ld
143
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claimed process." 146 The court further determined that the claims were narrow enough to avoid
preempting a natural phenomenon. 147 This claim was held to concern patentable subject matter
under §101. 148
VI. IMPACT OF MYRIAD AND THE FUTURE OF GENETIC DIAGNOSTIC METHOD CLAIMS
Since Prometheus was relied upon so heavily for both CAFC Myriad opinions, the
forthcoming Supreme Court Prometheus ruling is likely to impact the Myriad line of cases and
subsequent diagnostic patent cases. 149 It has been suggested that the Court's continued
involvement in the Prometheus line of cases indicates that the machine-or-transformation test is
not the appropriate method for determining patentability of diagnostic method claims. 150 Some
insight as to how the Supreme Court may analyze Prometheus can be found in the dissenting
opinion of Justice Breyer in LabCorp. 151 Justice Breyer, joined by Justices Stevens and Souter,
dissented from the dismissal after cert had originally been granted. 152 In his opinion, Justice
Breyer stated he would have held the disputed claim (methods for detecting vitamin B and folic
acid deficiencies in patients) invalid as patenting a natural phenomenon. 153 According to Justice
Breyer, the claimed process "is no more than an instruction to read some numbers in light of
medical knowledge." 154 As Justice Breyer's opinion is not a majority ruling, it has no binding

146
147

Jd

Jd at 1358 ("The claim does not cover all cells, all compounds, or all methods of determining the therapeutic
effect of a compound. Rather, it is tied to specific host cells transformed with specific genes and grown in the
presence or absence of a specific type of therapeutic. Moreover, the claim is tied to measuring a therapeutic effect
on the cells solely by changes in the cells' growth rate.").
148
Ass'nfor Molecular Pathology, 653 F.3d at 1358
149
Jacob D. Moore, Note, The Forgotten Victim in the Human Gene Patenting Debate: Pharmaceutical Companies,
63 FLA. L. REv. 1277, 1287 (suggesting that the viability of Myriad's method claims remains unresolved until a
Supreme Court opinion in Prometheus).
150
Jd. at 1287.
151
Metabolite Laboratories Inc., 548 U.S. at 125.
152
153
154

Jd.
Jd at 138.

ld. at 137.
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effect up on lower courts. 155 Indeed, the CAFC has rejected or declined to discuss his
reasoning. 156
Oral arguments at the Supreme Court for Prometheus seemed to focus on the issue of
preemption. 157 The Court must consider the line between natural phenomena and patentable
subject matter: how much "application" must there be to a law of nature to a particular process
before it is deemed patentable? 158 The decision is expected to be close, 159 and more likely to
provide additional guidance in light of specific circumstances of future cases than a definitive
legal principle.
Whatever the outcome of Prometheus is, it will impact the developing doctrine of
medical diagnostic patents. This is an important and controversial area of law, potentially
affecting scientific research and patient care as it relates to human genetics. 160 However, even if
the Prometheus decision invalidates the diagnostic method claims at issue in Myriad, other
laboratories will still be unable to complete diagnostic testing using the BRCAl/2 genes, as the
patents covering the genes themselves are still valid, and will potentially remain so until the
Supreme Court hears the Myriad case. 161

A. Policy Impact
Although Justice Breyer's LabCorp opinion162 has no binding effect upon lower courts,

155

Prometheus, 58 I F.3d at I350 n.3; Prometheus, 628 F.3d at I356 n.2.
Prometheus, 58 I F.3d at I350 n.3; Prometheus, 628 F.3d at I356 n.2.
157
Jonas Anderson, Summary ofMayo v. Prometheus Oral Argument, Patently-0 (Dec. 8, 20 I1, II :25 AM),
http://www.patentlyo.com/patent/201I/I2/summary-of-mayo-v-prometheus-oral-argument.html.
158Jd
156

159

Denise W. DeFranco, Mayo v. Prometheus Guest Post: The Hot-Button Issues, Patently-0 (Dec. 11,2011, 12:57
PM), http://www.patentlyo.com/patent/20 11/12/mayo-v-prometheus-guest-post-the-hot-button-issues.html.
160
Paradise, supra note 15 at 134.
161
Supreme Court: No Move Yet on Denying Human Gene Patents, Patently-0 (Feb. 21,2012, 12:42 PM),
http://www.patentlyo.com/patent/2012/02/supreme-court-no-move-yet-on-denying-human-gene-patents.html
(noting the link between the Prometheus decision and the Myriad case).
162
Metaholite Lahoratories, Inc., 548lJ.S. 124 (Rreyer, JJ., dissenting).
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the public policy arguments it discussed have been referenced in the Bilski/ 63 and Myriad Ii 64
opinions. Justice Breyer felt it was the Court's provision to "contribute to the important ongoing
debate, among both specialists and generalists, as to whether the patent system, as currently
administered and enforced, adequately reflects the 'careful balance' that 'the federal patent laws .
. . embod[y]. "' 165 Breyer recognized that patent restrictions may impact the ability of doctors to
provide optimal medical care, divert resources from providing medical care in order to avoid
patent infringement, and increase the cost of health care. 166
Experts have argued that the machine-or-transformation test as put forth in Bilski is not
well-suited for determining the patentability of the types of diagnostic and genetic testing
methods that are increasingly used in modem medicine. 167 Perhaps the Supreme Court will
modify the machine-or-transformation test, or disseminate a new test more suited for this type of
application when it announces its Prometheus decision in the near future.
The courts have made repeated calls to Congress to address method claim patentability
through legislation. One of the reasons Justice Breyer felt the Supreme Court should hear the
Laboratory Corp. case was to "help Congress determine whether legislation is needed." 168
Under the current law, medical practitioners who perform a patented medical or surgical
procedure on the body will not be held liable for patent infringement. 169 This exemption does
not apply to the use of patented pharmaceuticals or machines, or "biotechnology," though the

163

Bilski, 130 S. Ct. 3218 (Stevens, JJ., concurring) (referencing the argument that patents may inhibit research by
increasing costs and discourage the free exchange of information.).
164
Ass'nfor Molecular Pathology, 653 F.3d at 1380 (Bryson, J., dissenting).
165
Metabolite Laboratories, Inc., 548 U.S. at 138 (Breyer, JJ., dissenting) (citation omitted).
166
Metabolite Laboratories, Inc., 548 U.S. at 138 (Breyer, JJ., dissenting).
167
Brian P. Murphy and Daniel P. Murphy, Bilski's "Machine-or-Transformation" Test Uncertain Prognosis for
Diagnostic Methods and Personalized Medicine Patents, 20 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 755, 780
(2010).
168
Metabolite Laboratories, Inc., 548 U.S. at 138 (Breyer, JJ., dissenting).
169
35 U.S.C. §287(c) (2011).
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term ''biotechnology" is not defined in the statute. 170 One option may be for Congress to provide
a definition of "biotechnology" that includes all patents relating to genetic sequencing. Another
may be to provide an exemption for diagnostic testing similar to the "medical or surgical
procedure" currently existing.
There is evidence that Congress taking note of these issues. On September 16, 2011,
President Obama signed the Leahy-Smith America Invents Act into law. The Act provides for
substantial changes to the Patent office, 171 including a provision requiring the Director of the
USPTO to conduct a study "on effective ways to provide independent, confirming genetic
diagnostic test activity where gene patents and exclusive licensing for primary genetic diagnostic
tests exist." 172 The directives for the study appear to address many of the concerns raised by the
plaintiffs in Myriad regarding the impact of genetic diagnostic tests. 173 Depending on the
outcome of this study, future legislation may be enacted directly concerning these tests. If
Congress feels that patents on "genetic diagnostic tests" are detrimental to patient health, then it
is up to Congress to pass legislation as an appropriate remedy.
1. Arguments against the patentability of diagnostic method patents
Some critics of gene patenting argue that gene patenting is akin to a "land grab" over a
170 Jd
171

Press Release, The White House, President Obama Signs America Invents Act, Overhauling the Patent System to
Stimulate Economic Growth, and Announces New Steps to Help Entrepreneurs Create Jobs (Sept. 16, 2011)
(http://www.whitehouse.gov/the-press-office/2011/09/16/president-obama-signs-america-invents-act-overhaulingpatent-system-stim).
172

Leahy-Smith American Invents Act, Pub. L. No. 112-29, § 27, 125 Stat. 284 (2011).
Leahy-Smith American Invents Act; Pub. L. No. 112-29, § 27(b)(1)-(4), 125 Stat. 284 (2011) ("(b) ITEMS
INCLUDED IN STUDY.--The study shall include an examination ofat least the following: (1) The impact that the
current lack of independent second opinion testing has had on the ability to provide the highest level of medical care
to patients and recipients of genetic diagnostic testing, and on inhibiting innovation to existing testing and
diagnoses. (2) The effect that providing independent second opinion genetic diagnostic testing would have on the
existing patent and license holders of an exclusive genetic test. (3) The impact that current exclusive licensing and
patents on genetic testing activity has on the practice of medicine, including but not limited to: the interpretation of
testing results and performance of testing procedures. (4) The role that cost and insurance coverage have on access
to and provision of genetic diagnostic tests.").
173
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fmite number ofhuman genes. 174 Once the entire human genome has been isolated and patented,
researchers and doctors cannot legally utilize the patented genes without permission (in the form
of a license) from the patent holder. There is a fear that this will result in high costs on future
innovators and the underuse of genetic information, which will stunt further research.

175

A gene patent grant to a biotechnology firm or organization will exclude many ou1ers
who initially worked on the research leading to the patented test. 176 This policy is often counter
to the spirit of scientific research. 177 The Breast Cancer Linkage Consortium invited
membership to any researcher willing to share results from his or her studies. 178 The Human
Genome Project openly disseminated the completed gene sequences as soon as they were
completed. 179 Much of the information used by Myriad was already in the public domain
because of these kinds of policies. 180
Several of the plaintiffs represented by the ACLU in the Myriad cases are patients who
wish to obtairt the BRCAl/2 genetic testing, but are unable to afford the test. 181 Due to the
exclusionary nature of a patent grant, owners of a patent are able to have almost a monopolistic
control over the patented subject matter. 182 This concept is especially evident in genetic testing
"because either there is no way to 'invent around' and put similar products on the market, or
174

Beyan & Jensen, supra note 6.
Id
176
Matthijs & Van Ommen, supra note 4 at 323 ("Allowing patent protection to only one organisation tends to
ignore and disregard in terms of IP rights the contribution of all the other collaborators.").
11s

177

Id. at 322-323.
Paradise, supra note 15 at 143.
179
Nat'l Human Genome Research Inst., Nat'l Institutes of Health, 111.e Human Genome Project Completion:
Frequently Asked Questions, http://www.genome.gov/11006943 (last updated Oct. 30, 2010) ("Every part of the
genome sequenced by the Human Genome Project was made public immediately - in fact, new data on the genome
is posted every 24 hours.").
180
Paradise, supra note 15 at 143; see, e.g., Yoshio Moo, et al., A Strong Candidate for the Breast and Ovarian
Cancer Susceptibility Gene BRCAJ, Science, 66, Oct. 1994, http://www.sciencemag.org/
content/266/5182/66.full.pdf.
181
Ass'nfor Molecular Pathology, 102 F.Supp.2d at 188-90.
182
Rebecca S. Eisenberg, Genomic Patents and Product Development Incentives, in HUMAN DNA: LAW AND
POLICY INTERNATIONAL AND CO:MPARATIVE PERSPECTIVES 373, 374 (Bartha Maria Knoppers ed., 1997).
178
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because the diagnostic laboratories lack the power (i.e. a patent portfolio or a suitable substitute
for the diagnostic test) to negotiate reasonable conditions." 183 This has lead to inflation in the
cost of Myriad's test.

184

Myriad has likewise impeded patient access to the BRCAl and BRCA2 genetic test, as it
did not license the test or did not do so at terms acceptable to laboratories. 185 Consequently "all
the tests would have to be performed in its own laboratories in Utah." 186 In the United States,
gene patent holders have successfully deterred other laboratories from performing diagnostic
tests out of fear of patent infringement lawsuits. 187 A major concern is that doctors and patients
can no longer obtain second opinions on tests that can carry considerable medical implications,
such as breast or ovarian cancer. 188
The Myriad patents have also inhibited the development of new tests for BRCAl and
BRCA2 gene mutations. 189 The quality of the diagnostic test may be impacted by the Myriad
decision. Different mutations in the BRCAl and BRCA2 genes were found by different
laboratories using many different testing techniques. 190 "When only a single lab offers a given
test it is impossible to apply the 'gold standard' of quality assurance--proficiency testing--which
requires analysis of the same sample by more than one provider." 191 Without the collaborative
effort of many resources, the further progression of diagnostic genetic tests is restricted.
2. Arguments for Diagnostic Patents

183

Matthijs & Van Ommen, supra note 4 at 321.
Crichton, supra note 16 ("[A] test for breast cancer that could be done for $1,000 now costs $3,000.").
185
Matthijs & Van Ommen, supra note 4 at 320.
186 ld.
187
Jd. at 321.
188
Rochelle P. Dreyfuss & James P. Evans, From Bilski Back to Benson: Preemption, Inventing Around, and the
Case ofGenetic Diagnostics, 63 STAN. L. REv. 1349, 1366 (2011).
189
Matthijs & Van Ommen, supra note 4 at 321(''[R]egrettably, more than ten years were lost for the development
of novel technologies applied to BRCA.")
190
ld at 322.
191
Dreyfuss & Evans, supra note 188 at 13 66.
184
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Proponents of diagnostic method patenting emphasize that the purpose of the U.S. patent
system is to encourage commercial development of new technologies. 192 The right of exclusion
afforded a patent owner "is how patents motivate flrms to invest in [research and development],
an investment that might be unprofitable if free riders were permitted to enter the market for new
tecili1ologies tt~at prove w1success:ful without having shared i1·1 the initial cost and risk." 193
During the Myriad cases, the ACLU launched a high-profile campaign that attracted
media attention to a polarizing issue. 194 However, some would argue that the ACLU concerns
are exaggerated: "Generally speaking, published statements criticizing human gene patents tend
to provide little documented evidence of specific instances where such fears have actually
manifested themselves." 195 While patents do convey a right to exclude, that right is not self...,.
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A patent 1s only restrictive when the patent owner successtully brmgs an act1on tor

patent infringement. 197
Advocates of genetic method patents may find support in the current practices of the
USPTO. The USPTO allows for certain patent applications to be made "special" which enables
an application to be examined earlier. 198 Among the criteria for making a patent application
eligible for "special" status are applications relating to the treatment and cure for HIVI AIDS and
cancer. 199 One could argue that the diagnostic patents allowed to Myriad Genetics (method of

192

Eisenberg, supra note 182 at 373.

193

I d. at 374.

194

Lauren M. Dune, Note, "Come, Let us Return to Reason": Association ofMolecular Pathology v. USPTO, 20
DePaul J. Art, Tech. & Intell. Prop. L. 473,475 (2010); see also Michael Crichton, Patenting Life, N.Y. TIMES, Feb.
13,2007, http://www.nytim.es.com/2007/02/13/opinion/13crichton.html ("For years we've been promised the
coming era of personalized medicine - medicine suited to our particular body makeup. Gene patents destroy that
dream.")
195
Holman, Christopher M., The Impact ofHuman Gene Patents on Innovation and Access: A Survey ofHuman
Gene Patent Litigation, 76 UMKC L. REv. 295, 299 (2007).
196
I d. at 305.
197 ld
198

MANuAL OF PATENT EXAMINING PROCEDURE§ 708.02(X) (8th ed. 2001) ("New applications ordinarily are taken
up for examination in the order of their effective United States filing dates.").
199
Jd e'In view of the importance of developing treatments and cures for HIV/AIDS and cancer and the desirability
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seeking potential cancer therapies) are akin to the patent applications afforded special status at
the USPTO. Determining the genetic cause of serious diseases could lead to breakthroughs in
treatments. Early detection of genetic predisposition for certain forms of cancer will aid doctors
in effectively counseling their patients.200 It follows then, that the USPTO fmds value in
granting patent protection to inventions relating to ameliorating debilitating and serious diseases.
B. Analysis in Myriad affecting genetic method patents

Both the ACLU and Myriad Genetics independently petitioned the CAFC for rehearing
following the decision. 201 Both requests were denied, leaving certiorari by the Supreme Court as
the only option remaining for either party? 02 The Supreme Court may vacate the CAFC ruling
and remand for reconsideration in light of its decision in Prometheus, as it did for Prometheus
after Bilski. Many believe it is highly likely that the Supreme Court will hear a case involving
the DNA composition claims, and such a case would invariably impact the related method
claims?03 The ACLU has filed a petition for a writ of certiorari asking the Court to address
whether or not human genes are patentable. 204 The Court has deferred deciding whether or not to
grant the writ of certiorari, perhaps due to the potential influence the pending Prometheus
opinion will have on Myriad. 205
After the CAFC ruling, Myriad Genetics' claims for isolated DNA and method of
screening potential cancer therapeutics are still valid, while the method claims of analyzing and

of prompt disclosure of advances made in these fields, the U.S. Patent and Trademark Office will accord 'special'
status to patent applications relating to lllV/AIDS and cancer.").
200
BRCAJ and BRCA2: Cancer Risk and Genetic Testing, NATIONAL CANCER INSTITUTE,
http://www.cancer.gov/cancertopics/factsheet!risk/brca (last visited Jan. 22, 2012).
201
Mary Beth Tung, Myriad: Isolated DNA claims from "ball bats in trees," and "kidneys" to "magic
microscopes.", IPWatchdog (Sept. 25,2011, 8:00AM), http://ipwatchdog.com/2011/09/25/myriad~isolated-dna
claims/id=19397/.
202

Jd
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Hodes, supra note 21 at 234.
Petition for Writ of Certiorari, Ass 'nfor Molecular Pathology (2011).
205
Supreme Court: No Move Yet on Denying Human Gene Patents, Patently~O (Feb. 21, 2012, 12:42 PM),
http://www.patentlyo.com/patent/2012/02/supreme-court-no-move-yet-on-denying-human-gene-patents.html.
204
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comparing the isolated DNA sequences are invalid.206 In theory, other hospitals and laboratories
are now able to offer BRCAl and BRCA2 gene mutation diagnostic testing; however, in order to
perform such testing, they will be unable to use the isolated BRCAl and BRCA2 genes as those
are still covered by a valid patent. It is thus necessary for clinicians to deal with Myriad
Genetics, who has been identified in a report by the Health and Human Services Secret&y's
Advisory Committee on Genetics, Health, and Society (SACGHS) as raising barriers to patient
access to breast cancer diagnoses, and failing to deposit new mutations into public databases. 207
The inability to invent around a patented technology creates problems for both product markets
and innovation markets. 208
VII. CONCLUSION
During the past twenty years great strides have been made regarding the diagnosis and
treatment of several genetic diseases. Much of this is owed to a great deal of time and resources
by teams of researchers, several of whom now seek patent protection for their inventions. But
where is the appropriate line between protecting and encouraging innovation and creating
barriers for doctors who want to use these tests and treatments to care for patients? The judicial
response has at times been as dynamic as the controversy surrounding the cases. Myriad has
shown that, for now, the CAFC is willing to uphold patents related to isolated genetic sequences
and diagnostic methods utilizing genetic sequences. Within the near future the Supreme Court
will decide if the CAFC's approach to method patents is correct. Meanwhile, the America
Invents Act indicates that the legislative branch is starting to pay attention to this very important
issue.
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Federal Circuit: Isolated Human DNA Molecules are Patentable, Patently-0 (July 29,2011, 12:32 PM)
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